Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) are CF-causing. CFTR modulators target variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing variants highlighting unmet needs. Alternat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jiafen, He, Gengming, Wang, Cheng, Bartlett, Claire, Panjwani, Naim, Mastromatteo, Scott, Lin, Fan, Keenan, Katherine, Avolio, Julie, Halevy, Anat, Shaw, Michelle, Esmaeili, Mohsen, Côté-Maurais, Guillaume, Adam, Damien, Bégin, Stéphanie, Bjornson, Candice, Chilvers, Mark, Reisman, Joe, Price, April, Parkins, Michael, van Wylick, Richard, Berthiaume, Yves, Bilodeau, Lara, Mateos-Corral, Dimas, Hughes, Daniel, Smith, Mary J., Morrison, Nancy, Brusky, Janna, Tullis, Elizabeth, Stephenson, Anne L., Quon, Bradley S., Wilcox, Pearce, Leung, Winnie M., Solomon, Melinda, Sun, Lei, Brochiero, Emmanuelle, Moraes, Theo J., Gonska, Tanja, Ratjen, Felix, Rommens, Johanna M., Strug, Lisa J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993824/
https://www.ncbi.nlm.nih.gov/pubmed/35396391
http://dx.doi.org/10.1038/s41525-022-00299-9

Ejemplares similares

Ejemplares similares